The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The observations are of procedural in nature and will be responded to within the stipulated time
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Subscribe To Our Newsletter & Stay Updated
